

Learner Notification

MED Learning Group

The Emerging Standard of Care: Immunotherapy in Non-Melanoma Skin Cancer

June 29, 2023 – June 29, 2024

Online

Acknowledgement of Financial Commercial Support

Regeneron Pharmaceuticals, Inc.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Discuss cutaneous squamous cell carcinoma tumor cell dissemination and post-surgical recurrence.
2. Evaluate the application of immune checkpoint inhibition in the neo-adjuvant setting of cutaneous squamous cell carcinoma.
3. Review the efficacy and safety data of immunotherapy in patients with either advanced basal cell carcinoma or advanced cutaneous squamous cell carcinoma.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1--6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interst: Relationship
Felecia	Beachum	NA
Naomi	De Brito	NA
Kim L.	Farina	NA
Matthew	Frese	NA
Christina	Gallo	NA
Nicole	Longo	NA
Aimee	Meissner	NA
David M.	Miller	Merck, EMD Serono, Regeneron, Sanofi Genzyme, Pfizer, Castle Biosciences, Checkpoint Therapeutics: Scientific/Medical Advisory Board, Checkpoint Therapeutics, Avstera Therapeutics: Stock Shareholder, Regeneron, Kartos Therapeutics. Neolmmune Tech, Inc, Project Data Sphere, ECOG-ACRIN, the American Skin Association: Research Funding
Vishal A.	Patel	He has received consulting fees from Regeneron, Sanofi, PhD Biosciences, Almirall, and Jounce Therapeutics. He is on the Speakers Bureau for Regeneron,

		Sanofi, and Almirall, and has ownership interests in Avstera Therapeutics, Lazarus AI, and Science 37.
Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email Certificate@AmedcoEmail.com